Baricitinib
(Die Seite wurde neu angelegt: „{{up|JAK Janus Kinase}} 'Baricitinib is a reversible Janus-associated kinase (JAK)-inhibitor that interrupts the signaling of multiple cytokines implicated in…“)
Aktuelle Version vom 11. April 2021, 19:35 Uhr
| JAK Janus Kinase |
'Baricitinib is a reversible Janus-associated kinase (JAK)-inhibitor that interrupts the signaling of multiple cytokines implicated in COVID-19 immunopathology.32542785'
32259575 ä. BARICITINIB - A JANUASE KINASE INHIBITOR - NOT AN IDEAL OPTION FOR MANAGEMENT OF COVID 19
32333918 ä. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
32032529 2020. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
32473600 2020. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.
32251638 2020. Baricitinib for COVID-19: a suitable treatment?
32251639 2020. Baricitinib for COVID-19: a suitable treatment? - Authors reply
32437019 2020. Baricitinib: A chance to treat COVID-19?
32542785 2020. Baricitinib: A review of pharmacology, safety and emerging clinical experience in COVID-19.
32597466 2020. Use of Baricitinib in Patients with Moderate and Severe COVID-19.
32592703 2020. Retrospective, multicenter study on the impact of baricitinib in COVID-19 moderate pneumonia.
32583654 2020. Baricitinib en el tratamiento de infeccion por SARS-CoV-2.
32642806 2020. Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab.
32645632 2020. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
32670785 2020. Successful recovery from COVID-19 pneumonia after receiving baricitinib, tocilizumab, and remdesivir. A case report: Review of treatments and clinical role of computed tomography analysis.
32693646 2020. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
32797226 2020. Response to Correspondence: Baricitinib - Impact on COVID-19 Coagulopathy? Jorgensen et. al.
32797239 2020. Baricitinib as treatment for COVID-19: friend or foe of the pancreas?
32797235 2020. Response to Correspondence: Baricitinib as Treatment of COVID-19 Friend or Foe of the Pancreas? Cerda-Contreras et.al.
| 32797237 2020. Baricitinib: Impact on COVID-19 coagulopathy? |
32809969 2020. Baricitinib restrains the immune dysregulation in severe COVID-19 patients.
32840116 2020. Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19?
32901809 2020. The Emergence of Baricitinib: A Story of Tortoises Versus Hares.
33020836 2020. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study.
| 33278358 2020. Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques. |
